Physician profile
Dylan Grant Smith
NPI 1194217364
$1,700.41
in general payments reported to CMS, 2019-2025
24 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $130 · 2022: $338 · 2023: $425 · 2024: $328 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $563.28 | 2022-2025 | |
| Abbvie INC. | $198.11 | 2021-2025 | Linzess, Viberzi |
| Lilly USA, LLC | $188.33 | 2022-2025 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $95.54 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.47 | 2025 | |
| Xeris Pharmaceuticals, INC. | $68.35 | 2023-2024 | Keveyis |
| Novo Nordisk INC | $66.38 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $66.37 | 2022 | |
| Amarin Pharma, INC. | $49.52 | 2021 | |
| Abbott Laboratories | $41.17 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.88 | 2022 | |
| Merck Sharp & Dohme LLC | $31.10 | 2021-2022 | |
| Inspire Medical Systems, INC. | $27.89 | 2025 | Inspire |
| Ultragenyx Pharmaceutical INC. | $27.09 | 2021-2023 | |
| Abiomed | $19.88 | 2024 | Impella |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $19.76 | 2024 | Dexcom G6 Transmitter |
| Seqirus USA INC | $18.64 | 2024 | Flucelvax |
| E.R. Squibb & Sons, L.L.C. | $17.65 | 2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.19 | 2022 | |
| Genzyme Corporation | $13.64 | 2023 | |
| Impel Pharmaceuticals INC. | $13.23 | 2023 | Trudhesa |
| Hologic Sales and Service, LLC | $13.19 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.42 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $11.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.